|
|
| Line 1: |
Line 1: |
| [[Image:1i5x.gif|left|200px]] | | {{Seed}} |
| | [[Image:1i5x.png|left|200px]] |
|
| |
|
| <!-- | | <!-- |
| Line 9: |
Line 10: |
| {{STRUCTURE_1i5x| PDB=1i5x | SCENE= }} | | {{STRUCTURE_1i5x| PDB=1i5x | SCENE= }} |
|
| |
|
| '''HIV-1 GP41 CORE'''
| | ===HIV-1 GP41 CORE=== |
|
| |
|
|
| |
|
| ==Overview==
| | <!-- |
| Membrane fusion by human immunodeficiency virus type 1 (HIV-1) is promoted by the refolding of the viral envelope glycoprotein into a fusion-active conformation. The structure of the gp41 ectodomain core in its fusion-active state is a trimer of hairpins in which three antiparallel carboxyl-terminal helices pack into hydrophobic grooves on the surface of an amino-terminal trimeric coiled coil. In an effort to identify amino acid residues in these grooves that are critical for gp41 activation, we have used alanine-scanning mutagenesis to investigate the importance of individual side chains in determining the biophysical properties of the gp41 core and the membrane fusion activity of the gp120-gp41 complex. Alanine substitutions at Leu-556, Leu-565, Val-570, Gly-572, and Arg-579 positions severely impaired membrane fusion activity in envelope glycoproteins that were for the most part normally expressed. Whereas alanine mutations at Leu-565 and Val-570 destabilized the trimer-of-hairpins structure, mutations at Gly-572 and Arg-579 led to the formation of a stable gp41 core. Our results suggest that the Leu-565 and Val-570 residues are important determinants of conserved packing interactions between the amino- and carboxyl-terminal helices of gp41. We propose that the high degree of sequence conservation at Gly-572 and Arg-579 may result from selective pressures imposed by prefusogenic conformations of the HIV-1 envelope glycoprotein. Further analysis of the gp41 activation process may elucidate targets for antiviral intervention.
| | The line below this paragraph, {{ABSTRACT_PUBMED_11602754}}, adds the Publication Abstract to the page |
| | (as it appears on PubMed at http://www.pubmed.gov), where 11602754 is the PubMed ID number. |
| | --> |
| | {{ABSTRACT_PUBMED_11602754}} |
|
| |
|
| ==About this Structure== | | ==About this Structure== |
| Line 28: |
Line 32: |
| [[Category: Hiv-1 inhibition]] | | [[Category: Hiv-1 inhibition]] |
| [[Category: Membrane fusion]] | | [[Category: Membrane fusion]] |
| ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri May 2 19:37:05 2008'' | | |
| | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 1 10:28:20 2008'' |